Search
for

    Glossary Chlormadinone Acetate

    synthetic hormone used in contraceptives and hormone therapy

    Chlormadinone Acetate (CMA) is a synthetic progestin, a type of hormone similar to the natural hormone progesterone. It is commonly used in hormonal contraceptives and hormone replacement therapy to regulate menstrual cycles, treat endometriosis, and manage symptoms of menopause. Additionally, it has anti-androgenic properties, which means it can help reduce the effects of male hormones, making it useful in treating conditions like acne and hirsutism (excessive hair growth).

    Research 10 of 151

    1. Profile of the progesterone derivative chlormadinone acetate — Pharmocodynamic properties and therapeutic applications Contraception · 2009 · 33 citations
    2. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone) Journal of Endocrinological Investigation · 2019 · 25 citations
    3. Ethinylestradiol/Chlormadinone Acetate American Journal of Clinical Dermatology · 2011 · 13 citations
    4. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception Journal of the European Academy of Dermatology and Venereology · 2012 · 6 citations
    5. Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders American Journal of Clinical Dermatology · 2011 · 4 citations
    6. Ethinylestradiol/Chlormadinone Acetate Drugs · 2004 · 1 citations
    7. Progress on clinical applications of chlormadinone acetate Chin J Reprod Contracep · 2018
    8. Effects of two estroprogestins containing ethynilestradiol 30mug and drospirenone 3 mg and ethynilestradiol 30mug and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations Gynecological endocrinology · 2008 · 31 citations
    9. Acne Resolution Rates: Results of a Single-Blind, Randomized, Controlled, Parallel Phase III Trial with EE/CMA (Belara<sup>®</sup>) and EE/LNG (Microgynon<sup>®</sup>) Dermatology · 2001 · 88 citations
    10. Combined hormonal contraception and venous thromboembolism The European Journal of Contraception & Reproductive Health Care · 2007 · 46 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →